Compare Inovio Pharmaceuticals Inc (INO) vs Atlassian Corporation PLC (TEAM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs Atlassian Corporation PLC — how do they compare? Inovio Pharmaceuticals Inc trades at $1.08 (market cap $112.19M), while Atlassian Corporation PLC trades at $203.92 (market cap $51.53B). The key difference: Atlassian Corporation PLC is far larger — about 459.3× Inovio Pharmaceuticals Inc's market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Inovio Pharmaceuticals Inc for 43 Days and Atlassian Corporation PLC for 64 Days on average.
| INO | TEAM | |
|---|---|---|
Market Cap | $112.19M | $51.53B |
Volume | 3,201,278 | 2,904,511 |
Sector | Health | Technology |
52-Week High | $2.65 | $203.57 |
52-Week Low | $0.66 | $57.15 |
Typical Hold Time | 43 Days | 64 Days |
Enterprise Value | $83.51M | $51.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Inovio Pharmaceuticals trades at $1.155, up 2.21% today, with a bearish technical signal despite recent earnings beats. The company faces significant fundamental challenges with minimal revenue of $65,340 and substantial losses, reflected in a -130,000% net margin. Key catalyst is the October 30, 2026 FDA decision on INO-3107 for recurrent respiratory papillomatosis, with analyst consensus leaning bullish at a $2.75 price target.
Investment outlook hinges on FDA approval success; upside exists if INO-3107 gains approval, but persistent cash burn and lack of commercial revenue pose substantial risks. The stock remains speculative with high volatility expected around regulatory milestones.
Atlassian (TEAM) trades at $195.67, up 0.87% with bullish technical signals and strong analyst support. The stock shows improving fundamentals with revenue growth from $2.8B in 2022 to $5.22B in 2025, though net margins remain negative. Recent earnings beats and AI-driven cloud adoption provide momentum, with the current price near resistance at $196.
Outlook remains positive given robust cloud growth and AI integration, but high valuations and persistent losses pose risks. Wall Street consensus is strongly bullish with 30 buy ratings and a $191.16 target, though the stock trades above this level. Key risks include execution challenges and competitive pressures in the enterprise software space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →
